Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues

R. Giardino, M. Fini, V. Bonazzi, R. Cadossi, A. Nicolini, A. Carpi

Research output: Contribution to journalArticle

Abstract

Electrochemotherapy (ECT) is a new treatment for metastatic nodules of solid tumors on the skin or subcutaneous tissue. ECT is a combination of a physical effect, cell membrane poration, and cytotoxic drug administration. Cell membrane poration is achieved by applying short intense electric filed pulses. Pore formation on the cell membrane allows low permeant drugs like bleomycin or cisplatin to enter the cell and thus locally increase their toxicity: up to 10.000 times for bleomycin and 80 times for cisplatin. ECT has been investigated in a multicenter study European Standard Operating Procedures for Electrochemotherapy (ESOPE) that demonstrates how by ECT over 80% of the cutaneous or subcutaneous metastatic nodules can be healed, thus confirming the results of previous studies. ECT efficacy is independent of tumor histology. The experience gathered in the ESOPE study allowed to prepare standard operating procedures that are key to the dissemination of the technology. ECT is safe effective, the treatment is completed in one session usually on an out-patient basis with minimum side-effects. ECT is cost-effective and, although palliative, it ameliorates patients' quality of life. ECT is the treatment of choice for tumors refractory to conventional treatment, can be used in form of cytoreductive therapy before conventional treatment for organ sparing and functions saving, finally can be adopted to treat hemorrhagic or painful nodules, it can be applied in previously irradiated areas.

Original languageEnglish
Pages (from-to)458-462
Number of pages5
JournalBiomedicine and Pharmacotherapy
Volume60
Issue number8
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Electrochemotherapy
Bleomycin
Cell Membrane
Cisplatin
Organ Sparing Treatments
Therapeutics
Neoplasms
Skin
Subcutaneous Tissue
Pharmaceutical Preparations
Multicenter Studies
Histology

Keywords

  • Electrochemotherapy
  • Electroporation
  • Tumor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues. / Giardino, R.; Fini, M.; Bonazzi, V.; Cadossi, R.; Nicolini, A.; Carpi, A.

In: Biomedicine and Pharmacotherapy, Vol. 60, No. 8, 09.2006, p. 458-462.

Research output: Contribution to journalArticle

Giardino, R. ; Fini, M. ; Bonazzi, V. ; Cadossi, R. ; Nicolini, A. ; Carpi, A. / Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues. In: Biomedicine and Pharmacotherapy. 2006 ; Vol. 60, No. 8. pp. 458-462.
@article{f7d496376209414f8b21a74108738a18,
title = "Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues",
abstract = "Electrochemotherapy (ECT) is a new treatment for metastatic nodules of solid tumors on the skin or subcutaneous tissue. ECT is a combination of a physical effect, cell membrane poration, and cytotoxic drug administration. Cell membrane poration is achieved by applying short intense electric filed pulses. Pore formation on the cell membrane allows low permeant drugs like bleomycin or cisplatin to enter the cell and thus locally increase their toxicity: up to 10.000 times for bleomycin and 80 times for cisplatin. ECT has been investigated in a multicenter study European Standard Operating Procedures for Electrochemotherapy (ESOPE) that demonstrates how by ECT over 80{\%} of the cutaneous or subcutaneous metastatic nodules can be healed, thus confirming the results of previous studies. ECT efficacy is independent of tumor histology. The experience gathered in the ESOPE study allowed to prepare standard operating procedures that are key to the dissemination of the technology. ECT is safe effective, the treatment is completed in one session usually on an out-patient basis with minimum side-effects. ECT is cost-effective and, although palliative, it ameliorates patients' quality of life. ECT is the treatment of choice for tumors refractory to conventional treatment, can be used in form of cytoreductive therapy before conventional treatment for organ sparing and functions saving, finally can be adopted to treat hemorrhagic or painful nodules, it can be applied in previously irradiated areas.",
keywords = "Electrochemotherapy, Electroporation, Tumor",
author = "R. Giardino and M. Fini and V. Bonazzi and R. Cadossi and A. Nicolini and A. Carpi",
year = "2006",
month = "9",
doi = "10.1016/j.biopha.2006.07.016",
language = "English",
volume = "60",
pages = "458--462",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "8",

}

TY - JOUR

T1 - Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues

AU - Giardino, R.

AU - Fini, M.

AU - Bonazzi, V.

AU - Cadossi, R.

AU - Nicolini, A.

AU - Carpi, A.

PY - 2006/9

Y1 - 2006/9

N2 - Electrochemotherapy (ECT) is a new treatment for metastatic nodules of solid tumors on the skin or subcutaneous tissue. ECT is a combination of a physical effect, cell membrane poration, and cytotoxic drug administration. Cell membrane poration is achieved by applying short intense electric filed pulses. Pore formation on the cell membrane allows low permeant drugs like bleomycin or cisplatin to enter the cell and thus locally increase their toxicity: up to 10.000 times for bleomycin and 80 times for cisplatin. ECT has been investigated in a multicenter study European Standard Operating Procedures for Electrochemotherapy (ESOPE) that demonstrates how by ECT over 80% of the cutaneous or subcutaneous metastatic nodules can be healed, thus confirming the results of previous studies. ECT efficacy is independent of tumor histology. The experience gathered in the ESOPE study allowed to prepare standard operating procedures that are key to the dissemination of the technology. ECT is safe effective, the treatment is completed in one session usually on an out-patient basis with minimum side-effects. ECT is cost-effective and, although palliative, it ameliorates patients' quality of life. ECT is the treatment of choice for tumors refractory to conventional treatment, can be used in form of cytoreductive therapy before conventional treatment for organ sparing and functions saving, finally can be adopted to treat hemorrhagic or painful nodules, it can be applied in previously irradiated areas.

AB - Electrochemotherapy (ECT) is a new treatment for metastatic nodules of solid tumors on the skin or subcutaneous tissue. ECT is a combination of a physical effect, cell membrane poration, and cytotoxic drug administration. Cell membrane poration is achieved by applying short intense electric filed pulses. Pore formation on the cell membrane allows low permeant drugs like bleomycin or cisplatin to enter the cell and thus locally increase their toxicity: up to 10.000 times for bleomycin and 80 times for cisplatin. ECT has been investigated in a multicenter study European Standard Operating Procedures for Electrochemotherapy (ESOPE) that demonstrates how by ECT over 80% of the cutaneous or subcutaneous metastatic nodules can be healed, thus confirming the results of previous studies. ECT efficacy is independent of tumor histology. The experience gathered in the ESOPE study allowed to prepare standard operating procedures that are key to the dissemination of the technology. ECT is safe effective, the treatment is completed in one session usually on an out-patient basis with minimum side-effects. ECT is cost-effective and, although palliative, it ameliorates patients' quality of life. ECT is the treatment of choice for tumors refractory to conventional treatment, can be used in form of cytoreductive therapy before conventional treatment for organ sparing and functions saving, finally can be adopted to treat hemorrhagic or painful nodules, it can be applied in previously irradiated areas.

KW - Electrochemotherapy

KW - Electroporation

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=33748890908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748890908&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2006.07.016

DO - 10.1016/j.biopha.2006.07.016

M3 - Article

C2 - 16930935

AN - SCOPUS:33748890908

VL - 60

SP - 458

EP - 462

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 8

ER -